SCHEMBL31019286

SCHEMBL31019286

Fc1cnc2c[nH]nc2c1

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.32
AGBL2 Q5U5Z8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20303199 0.74 DYRK1A (0.48) PIM1
SCHEMBL26244811 0.69 KCNH2 (0.31)
SCHEMBL31317325 0.69 HPGDS (0.42)
SCHEMBL21672121 0.69
SCHEMBL22775718 0.69 GRIN2B (0.49)
SCHEMBL22749174 0.67 HPGDS (0.45)
SCHEMBL16178993 0.65 KDM4E (0.39)
SCHEMBL17697511 0.64 IDO1 (0.30)
SCHEMBL360968 0.64
SCHEMBL31378906 0.64 TLR9 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246969-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2024-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246969-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS CAMKK2, CAMKK1, CAMK1 PIM1 872/4885AGBL2 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.